<DOC>
	<DOCNO>NCT01891552</DOCNO>
	<brief_summary>- The recently introduce chemoembolization consider attractive new method term response treatment liver metastases colon cancer carcinoma ( LM-CRC ) . It appear particularly useful carry new embolization material . - An 80 % response rate report use TACE Irinotecan pre-loaded Beads patient liver metastasis colon cancer , pretreated 2 line chemotherapy . - Since great activity attain combination Cetuximab Irinotecan versus Cetuximab monotherapy , European Agency Evaluation Medicinal Products ( EMEA ) grant authorization use Cetuximab association irinotecan treatment irinotecan-refractory CRC-LM . - In study want collect data time progression tolerability use DEBIRI+Cetuximab LM-CRC</brief_summary>
	<brief_title>Observational Study Second Line Treatment Liver Metastases With DEBIRI Cetuximab</brief_title>
	<detailed_description>This observational study treatment related experience economical availability center . Primary objective : To collect data time progression ( local and/or distant progression ) administration Dc-Beads microspheres preloaded Irinotecan 200 mgr via hepatic intra-arterial locoregional delivery ( TACE ) in/without association standard weekly therapy Cetuximab . Secondary objective : To collect data tolerability treatment improvement quality life ( Edmonton Symptom Assessment System ( ESAS ) ) Treatment observation : Program A ( patient ) Day +1 : Lobar Infusion ( lobe dominant disease ) Irinotecan 100 mg preloaded 2 ml 70-150 µm M1 microspheres . Second lobar infusion Irinotecan 100 mg preloaded 2 ml 70-150 µm M1 microspheres administered time contralaterally TACE . Day +30 : The procedure repeat . Day +90 : In case response , third administration follow procedure repeat Program B ( Centers Cetuximab available ) 5.2 Cetuximab administer per standard scheme : Day -15 : loading dose 400 mg/mq i.v . 2-hour period Day +21 subsequent weekly administration : 250 mg/mq i.v . one hour period . It point administration Cetuximab continue follow timeline first infusion relative intra-arterial administration . Evaluation response Response must assess repeat follow examination Day 30 , Day 90 Day 120 start treatment : Chest-abdomen CAT scan without contrast medium ( refer Section 4 ) . Evaluation base Response Evaluation Criteria In Solid Tumors ( RECIST ) cancer marker ( CEA , Carbohydrate Antigen ( CA ) 19.9 ) Assessment quality life The Edmonton Symptom Assessment System ( ESAS ) use monitor health condition quality life . The questionnaire must fill patient unaided family member health care personnel , period 15 minute . Assessment quality life perform baseline visit Day 30 , Day 60 Day 120 start treatment . It important questionnaire complete patient undergoing physical examination , word discuss physician examination might give indication favorable unfavorable course disease . In provide questionnaire patient , physician explain complete without discuss content question , patient complete questionnaire , physician check question answer .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Unresectable hepatic metastasis colorectal carcinoma ( CRCLM ) 2 . Progression disease first line therapy contain Irinotecan complete least one month previously 3 . Performance status ( PS ) 02 4 . Biochemistry parameter within normal limit ( ALT gamma glutamyl transpeptidase exceed three time upper limit normal , total bilirubin exceed 2.5 mg/ml ) 5 . Adequate information subsequent write informed consent 6 . Life expectancy &gt; 3 month 7 . Patients KRAS wild type 1 . Extension disease great 50 % parenchymal liver ( confirm CAT scan MRI ) 2 . Brain metastases 3 . Severe confirm vascular disease 4 . Other concomitant malignancy except cutaneous basal cell carcinoma carcinoma situ uterine cervix 5 . Evidence significant disease uncontrolled diabetes , congestive heart failure , chronic renal insufficiency ( CRI ) 6 . Known hypersensitivity reaction towards component study drug 7 . Pregnant breastfeed woman woman childbearing potential making use effective contraceptive 8 . Family , psychological , social geographical circumstance prevent patient undergo followup comply protocol procedure 9 . Patients KRAS mutant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Colon Cancer , Liver Metastasis , DEBIRI , cetuximab , efficacy</keyword>
</DOC>